Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer

British Journal of Cancer

Volumn 91, Issue 5, 2004, Pages 873-878

  Nakata, B ^a   Takashima, T ^a   Ogawa, Y ^a   Ishikawa, T ^a   Hirakawa, K ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Carbohydrate antigen 15 3; Carcinoembryonic antigen; CYFRA 21 1; Cytokeratin 19 fragments; Monitoring

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKERATIN 19 FRAGMENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; KERATINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 4644325834     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602074     Document Type: Article

References (13)

1. American Society of Clinical Oncology (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guideline of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878
2. Brotheric I, Robson CN, Browell DA, Shenfine J, White MD, Cunliffe WJ, Shenton BK, Egan M, Webb LA, Lunt LG, Young JR, Higgs MJ (1998) Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 32: 301-308
3. Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S (2002) Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clin Chem Lab Med 40: 298-303
4. Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N, Ballesta AM (1994) Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumour Biol 15: 318-325
5. Moll R, Franke WW, Schiller DL (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24
6. Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada T, Sowa M (1996) Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 73: 1529-1532
7. Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K (2000) Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 89: 1285-1290
8. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66
9. Rodriguez CA, Cruz JJ, Martin T, Gomez A, Olaverri A, Hernandez M (2002) Letter and author reply: serum CYFRA 21-1 is one of the most reliable tumor marker for breast carcinoma. Cancer 95: 670-671
10. Sarwar M, Tomiyoshi K, Inoue T, Fukazawa K, Endo K (1994) CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay. Ann Nucl Med 8: 301-306
11. Sheard MA, Vojtesek B, Simickova M, Valik D (2002) Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85: 670-677
12. Stieber P, Bodenmuller H, Banauch D, Hasholzner U, Dessauer A, Ofenloch-Hahnle B, Jaworek D, Fateh-Moghadam A (1993) Cytokeratin 19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem 26: 301-304
13. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment, Offset Publication No 48. Geneva: World Health Organization